Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Tumor markers derived from nucleic acid components.

E Borek, T P Waalkes, C W Gehrke

Cancer Detection and Prevention

|January 1, 1983

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Methionine sulfoxide; a growth inhibiting analogue of glutamic acid.

Federation proceedings·2010

Same author

Biological acetylation of natural amino acids.

The Journal of biological chemistry·2010

Same author

Synthesis of cholesterol in surviving liver.

The Journal of biological chemistry·2010

Same author

Synthesis of cholesterol in liver slices.

Federation proceedings·2010

Same author

Regionalization of cancer control efforts in the u.s.a.

International quarterly of community health education·2010

Same author

Homologues of methionine sulfoxide as glutamin acid antimetabolites.

Federation proceedings·2010

Same journal

Melanoma metastasis to the breast: a diagnostic pitfall.

Cancer detection and prevention·2009

Same journal

Development of a rat model by 3,4-benzopyrene intra-pulmonary injection and evaluation of the effect of green tea drinking on p53 and bcl-2 expression in lung carcinoma.

Cancer detection and prevention·2009

Same journal

Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population.

Cancer detection and prevention·2009

Same journal

Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians.

Cancer detection and prevention·2009

Same journal

Epidemiology of primary brain tumors in the Middle Eastern population in California, USA 2001-2005.

Cancer detection and prevention·2009

Same journal

Lifetime consumption of alcoholic beverages and risk of 13 types of cancer in men: results from a case-control study in Montreal.

Cancer detection and prevention·2009

See all related articles

Cancer patients excrete elevated modified nucleosides from transfer RNA (tRNA) breakdown. These urinary markers, originating from hyperactive enzymes in malignant tissues, indicate cancer presence and monitor treatment effectiveness.

Area of Science:

Biochemistry
Oncology
Molecular Biology

Background:

Cancer patients exhibit elevated urinary modified nucleosides.
These nucleosides are primarily derived from transfer RNA (tRNA).
Enzymatic modifications of nucleosides occur post-synthesis at the macromolecular level.

Purpose of the Study:

To investigate the origin and significance of elevated urinary modified nucleosides in cancer patients.
To explore the potential of these nucleosides as universal malignancy biomarkers.
To assess their utility in monitoring cancer therapy.

Main Methods:

Analysis of urinary modified nucleosides in cancer patients.
Investigation of tRNA turnover and modifying enzyme activity in malignant tissues.

Related Experiment Videos

Correlation of marker levels with cancer diagnosis and treatment response.

Main Results:

Aberrant hyperactivity of tRNA modifying enzymes was observed in all malignant tissues studied.
Abnormally high tRNA turnover in malignant tissues contributes to elevated excretion products.
Urinary marker levels decrease rapidly following chemotherapy, indicating treatment effectiveness.

Conclusions:

Urinary modified nucleosides serve as potential universal biomarkers for malignancy.
These markers can aid in diagnosing challenging syndromes and monitoring therapeutic efficacy.
Clinical oncologists can utilize this data to personalize patient treatment protocols.